Dr. Miller is focused on finding ways to overcome myeloid immunosuppression to enable immunotherapy to be more effective in solid tumors. Using advanced single cell genomic, spatial transcriptomic, and ex vivo human modeling techniques, Dr. Miller has identified the dominant immunomodulatory activity programs in glioma-associated myeloid cells and the drivers of immunosuppression. He is now studying how to target these programs to reprogram the immune microenvironment of gliomas.